The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
about
Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateDistinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticityInactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.MLN4924 protects against bleomycin-induced pulmonary fibrosis by inhibiting the early inflammatory processTherapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinomaPevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivoCyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.The novel protective role of P27 in MLN4924-treated gastric cancer cells.Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivoTargeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agentsMLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells.Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.Differential control of retrovirus silencing in embryonic cells by proteasomal regulation of the ZFP809 retroviral repressor.TNF superfamily members promote hepatitis C virus entry via an NF-κB and myosin light chain kinase dependent pathway.Neddylation controls basal MKK7 kinase activity in breast cancer cells.MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcomaThe NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis.MLN4924 sensitizes monocytes and maturing dendritic cells for TNF-dependent and -independent necroptosis.Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.SYVN1, NEDD8, and FBXO2 Proteins Regulate ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitin-mediated Proteasomal Degradation.SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer.Protein neddylation and its alterations in human cancers for targeted therapy.Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.MIR21 is differentially expressed in the lymphoid tissue and modulated by stromal signalling in chronic lymphocytic leukaemia.Regulation of Mammalian DNA Replication via the Ubiquitin-Proteasome System.Inhibition of CRL-NEDD8 pathway as a new approach to enhance ATRA-induced differentiation of acute promyelocytic leukemia cells.
P2860
Q26798062-13E34F04-58C6-4873-8DB0-02F9961C9D2AQ28818350-71EA7793-3C31-46B4-81D3-6F05CA3AE5F4Q30276526-F8E6843D-BBD5-4B7E-B7C2-CC3212E570DBQ33427510-E45DAB8D-03B2-4F02-9631-9F540A264A97Q33623144-221A79DE-3962-43B6-93F5-11CD7A248179Q33792598-39966ABC-C000-450E-B48A-FCA7A57D3CCDQ33912016-8F6DDC54-39A1-4AF6-8137-CFFAD123D63FQ34505392-4D4A588C-90B8-40E9-A5C2-55EB717B440FQ35852684-5E847D47-4336-4EDC-96E8-BA69AF83B7F7Q36022283-86AB271D-4C9D-4EBE-9397-9727583174A4Q36072490-70273A03-4838-44C6-B0DF-E76BEF6F05D5Q36215406-3782FF9E-7909-488C-8536-60D369AFD3AAQ36293814-A0BB0D23-F3ED-4A53-ACEB-1D432C42B881Q36751575-EDDE03BC-D6C4-4A0E-ADD8-859C0EF2038BQ36785312-C61A9756-C2FD-41CC-9204-177606C22099Q36876973-A58CB1E2-CD6B-48AF-9A3B-B451B16F5425Q38231432-EC69F45E-1B90-4F12-B683-F1C7DBAD616AQ38712272-B74CB89F-3814-45DE-9A53-8A5A725EB345Q38734002-C70DE781-C9D9-473B-814B-EA1C02D67E56Q38862584-C857BD6A-573C-4CD3-B3CF-D66BBDFAE19DQ38972048-D9EE7CEB-028F-46F5-93C4-47277F374E3CQ40071281-00E10C42-2B26-42EF-8FDE-03137C9D793FQ40367498-432DBF71-7D29-482F-884E-8C71A4B12345Q40407185-25174B74-143A-4443-857B-0D46E1DFC6C5Q40545035-C0C55E07-7BBE-4371-9E58-2B4C2C00F7ECQ40851893-00FA48CE-2B06-4B7D-930A-E36370C2C120Q41849611-2A73E135-E4CE-47FC-90DE-4B7BD8E2B8B0Q42109896-59929E0D-EE27-4EB8-B8BC-A0BCDD0485DEQ45594363-D469BE89-E7A1-449A-9511-4CBA59A65594Q46353737-BE2DD97D-1386-4C15-8F76-066E61BA5CBFQ47163960-824687A2-0892-4349-BEF5-E016DDB8D624Q47253158-F911BE16-5D53-4F3C-A1DF-5398E85342F1Q48269744-F946D354-7979-45F1-A41B-A3EBE841BBF1Q48538797-74FCB024-D20B-47DB-82DD-727FD3F05682Q49787961-A7A6D154-3A4A-451B-BA1D-E787539CF668Q50889845-4E560FB5-A093-461F-B656-3F54487B7043Q50911306-2CBD4D4C-0F81-4892-82F8-100020A91180Q53628591-7A86016C-5934-4987-B5ED-8A430787F1B6Q55239552-B9076878-722A-4D98-8C53-8F82CBF2484FQ55332021-5D4B7412-9D5F-413A-99E0-44F54C7AA46E
P2860
The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Nedd8-activating enzyme in ...... lymphocytic leukemia B cells.
@en
The Nedd8-activating enzyme in ...... lymphocytic leukemia B cells.
@nl
type
label
The Nedd8-activating enzyme in ...... lymphocytic leukemia B cells.
@en
The Nedd8-activating enzyme in ...... lymphocytic leukemia B cells.
@nl
prefLabel
The Nedd8-activating enzyme in ...... lymphocytic leukemia B cells.
@en
The Nedd8-activating enzyme in ...... lymphocytic leukemia B cells.
@nl
P2093
P2860
P921
P1476
The Nedd8-activating enzyme in ...... lymphocytic leukemia B cells.
@en
P2093
Alan Eastman
Alexey V Danilov
J Claire Godbersen
Jennifer R Brown
Leigh Ann Humphries
Olga V Danilova
Peter E Kebbekus
P2860
P304
P356
10.1158/1078-0432.CCR-13-0987
P407
P577
2014-03-01T00:00:00Z